Number of suitable patients: CDEC mentioned the uncertainty in the amount of individuals with moderately serious to significant hemophilia B in Canada qualified for etranacogene dezaparvovec. Clinical specialists consulted by CADTH indicated that some patients who are labeled as having moderate or reasonable ailment could possibly have a significan